nomlabofusp - Ataxia UK

nomlabofusp

Large magnifying glass on light blue background

Larimar Therapeutics announces progress of the Nomlabofusp (CTI-1601) trial for Friedreich’s ataxia

1 Comment / Friedreich's ataxia, Friedreich's ataxia pharma news, Research News /

Following clearance by the US drug regulatory body the Food and Drug Administration (FDA) in July 2023, the pharmaceutical company Larimar Therapeutics has completed full enrolment and dosing of the

Larimar Therapeutics announces progress of the Nomlabofusp (CTI-1601) trial for Friedreich’s ataxia Read More »

Cart
Checkout - £0.00
  • 0
  • 1
Scroll to Top